Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Disorders of Hemostasis01:24

Disorders of Hemostasis

758
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
758
Coagulation01:09

Coagulation

5.7K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
5.7K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

6.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.6K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

5.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.0K
Introduction to Hemostasis01:05

Introduction to Hemostasis

6.8K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.

Annals of neurology·2026
Same author

Update from the National Hypertension Taskforce of Australia: prevalence, treatment and control rates of hypertension between 2022 and 2024 - implications and future directions.

Journal of hypertension·2026
Same author

Developing a patient reported measure on out-of-pocket healthcare expenditure among Aboriginal patients: a formative study.

Health promotion international·2026
Same author

Participation of Aboriginal and Torres Strait Islander People in Conventional Cardiac Rehabilitation Programs: Analysis of the Queensland Cardiac Outcomes Registry.

Heart, lung & circulation·2026
Same author

The Effectiveness, Facilitators, and Barriers of Digital Mental Health Services for First Nations People in Australia: Systematic Scoping Review.

Interactive journal of medical research·2026
Same author

CSANZ and ACRA Position Statement on Quality Use of Telehealth in Cardiovascular Care.

Heart, lung & circulation·2026

Related Experiment Video

Updated: Jun 16, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

826

Antithrombin III Levels and Outcomes Among Patients With Trauma.

David H Farrell1, Keeley M McConnell1, Jevgenia Zilberman-Rudenko1

  • 1Donald D. Trunkey Center for Civilian and Combat Casualty Care, Oregon Health & Science University, Portland.

JAMA Network Open
|August 15, 2024
PubMed
Summary

Antithrombin III deficiency in trauma patients is linked to worse outcomes, including increased bleeding and mortality. Monitoring antithrombin III levels may aid in risk assessment for trauma patients.

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.1K
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

713

Related Experiment Videos

Last Updated: Jun 16, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

826
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.1K
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

713

Area of Science:

  • Trauma and Critical Care Medicine
  • Coagulation and Hemostasis Research
  • Biochemistry and Molecular Biology

Background:

  • Patients with trauma often experience a complex coagulopathy, characterized by both bleeding and thrombosis.
  • Antithrombin III (ATIII), a key plasma regulator of coagulation, has a high incidence of deficiency observed in trauma patients.
  • Understanding the role of ATIII in trauma is crucial for managing thrombohemorrhagic complications.

Purpose of the Study:

  • To investigate the association between antithrombin III activity levels and the occurrence of thrombohemorrhagic complications in trauma patients.
  • To determine if ATIII deficiency correlates with specific adverse outcomes such as hemorrhage, deep vein thrombosis (DVT), and mortality.
  • To evaluate the clinical relevance of ATIII levels in predicting patient outcomes following trauma.

Main Methods:

  • A prospective cohort study involving 292 trauma patients admitted to a level I trauma center.
  • Data collection included quantification of antithrombin III activity, alongside monitoring of hemorrhage, DVT, pulmonary embolism, and mortality.
  • Patients were followed for 6 days post-admission, with analyses conducted on collected data.

Main Results:

  • Antithrombin III deficiency was associated with significantly fewer ventilator-free, hospital-free, and ICU-free days.
  • Patients with ATIII deficiency exhibited higher rates of progressive intracranial hemorrhage and thrombocytopenia.
  • While not significantly associated with DVT, patients who developed DVT had lower ATIII levels.

Conclusions:

  • Antithrombin III deficiency in trauma patients is linked to increased injury severity, hemorrhage, and mortality.
  • The findings suggest that antithrombin III levels could be a valuable biomarker for risk assessment in trauma care.
  • Further research may elucidate the therapeutic potential of modulating ATIII activity in trauma patients.